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Abstract
African American patients with colorectal cancer show higher mortality than their Caucasian counterparts. Biology might
play a partial role, and prior studies suggest a higher prevalence for microsatellite instability (MSI) among cancers from
African Americans, albeit patients with MSI cancers have improved survival over patients with non-MSI cancers, counter to
the outcome observed for African American patients. CD8+ T cell infiltration of colon cancer is postively correlated with MSI
tumors, and is also related to improved outcome. Here, we utilized a 503-person, population-based colon cancer cohort
comprising 45% African Americans to determine, under blinded conditions from all epidemiological data, the prevalence of
MSI and associated CD8+ T cell infiltration within the cancers. Among Caucasian cancers, 14% were MSI, whereas African
American cancers demonstrated 7% MSI (P = 0.009). Clinically, MSI cancers between races were similar; among microsatellite
stable cancers, African American patients were younger, female, and with proximal cancers. CD8+ T cells were higher in MSI
cancers (88.0 vs 30.4/hpf, P,0.0001), but was not different between races. Utilizing this population-based cohort, African
American cancers show half the MSI prevalence of Caucasians without change in CD8+ T cell infiltration which may
contribute towards their higher mortality from colon cancer.
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Introduction
Mortality from colon cancer is higher in African Americans
than Caucasians at every stage of disease [1,2]. While the mortality
difference could be in part related to clinical care or comorbidity,
it could also have contributions from differences from within the
cancer [3]. Prior studies have had insufficient numbers of African
Americans to adequately examine racial differences from tumor
characteristics that could influence mortality [4,5].
Microsatellite instability (MSI) is a genetic biomarker of
hypermutable colon cancers, driven by inactivation of the DNA
mismatch repair (MMR) system [6,7]. Its presence depicts a better
outcome for patients when compared to same-staged colon cancer
patients without MSI [3]. This may be due in part to neoantigens
generated by mutational frameshifts within coding regions of
specific genes as a consequence of inactivation of DNA MMR in
the colon cancer epithelial cell, attracting specific immune cells
that can help contain the tumor and limit metastasis [7,8]. In
particular, MSI colon cancers are associated with increased
intraepithelial CD8+ T cells when compared to microsatellite
stable (MSS) cancers [8–10], and many MSI cancers demonstrate
a ‘‘Crohn’s-like’’ lymphoid ‘‘granuloma’’ reaction histologically
within the epithelial component of the adenocarcinoma [7–9].
MSI cancers comprise 15–20% of all colon cancers, have diploid
cells and are inversely related to allelic loss. MSI cancers are more
likely to have mucinous features and poor differentiation at
histology, and ,70% are located proximal to the splenic flexure
within the colon. MSI cancers may progress more rapidly than
MSS cancers [7,11], and may drive sessile serrated adenomas into
cancers [12,13]. Additionally, patients with stage II/III MSI
cancers do not improve their survival with 5-fluorouracil-based
chemotherapy [14,15].
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Colon cancers from African Americans share some clinical and
epidemiological features with MSI cancers, but not others. For
instance, African Americans have more propensity for proximal
colon cancers and polyps, and tumor progression may be more
rapid based on the younger age for cancer diagnosis [1,2,16].
Some reports suggest more mucinous features anectdotally in
African American colon cancers [1]. These features would suggest
the prevalence of MSI would be relatively higher in African
American colon cancers. Conversely, African Americans tend to
present with advanced stage of disease, and possess poor 5-year
survival in contrast to that of patients with MSI cancers [1]. These
features would suggest MSI would be relatively lower in African
American colon cancers. Evaluation of African American colon
cancers for MSI has been sparse with only two groups having
published data, one showing an MSI frequency of 23% (7 of 31
samples) and the other with 48% (10 of 21 samples) among African
American cancers [4,5], suggesting a higher-than-average fre-
quency. Both groups utilized stored samples with linked racial
data; neither are studies from within a population. In the present
study, we utilized a population-based colon cancer cohort to more
accurately determine the frequency of MSI in African American
colon cancers. Our data indicate that there is half the frequency of
MSI among African American colon cancers compared to
Caucasian colon cancers, suggesting that once an African
American is diagnosed with colon cancer, the benefit from




Data were collected as part of the North Carolina Colon Cancer
Study (NCCCS), a population-based, case–control study conduct-
ed in 33 contiguous counties of central and eastern North
Carolina, including both rural and urban areas [17]. The counties
were selected to provide adequate representation by African
American and rural residents, and to avoid referral or selection
patterns that would impede case ascertainment and/or compli-
ance. The Institutional Review Board of the University of North
Carolina School of Medicine approved the original study protocol.
Cases were identified between October 1, 1996 and September
1, 2000 using a rapid ascertainment system implemented in
cooperation with the North Carolina Central Cancer Registry.
Eligible cases were between the ages of 40 and 80 yr, had
pathologically confirmed invasive adenocarcinoma of the colon,
and resided in the 33-county area. All eligible African American
patients were invited to participate. A random sample of
Caucasian patients of similar age (65 yr) and sex was drawn to
provide an equal number of African American and Caucasian
cases. Controls younger than 65 years from the same 33-county
area were selected from the Department of Motor Vehicles
Registry database, and controls 65 years and older were selected
from Health Care Financing Administration database.
Of 935 potential colon cancer cases identified (464 African
American, 471 Caucasian), physicians refused access for 31
African Americans and 35 Caucuasians, contact was incomplete
for 29 African Americans and 29 Caucasians, and 81 African
Americans and 45 Caucasians refused to participate. The overall
cooperation rate (interviewed/interviewed + refused) was 84%:
79% for African Americans, 89% for Caucasians. A further 33
patients were excluded because the quality of the interview was
judged inadequate. Consequently, there were 643 cases: 294
African Americans and 349 Caucasians. The overall cooperation
rate for controls was 62%: 59% for African Americans and 65%
for Caucasians; 1048 controls, 437 African American and 611
Caucasian participants.
Cases and controls were selected using randomized recruitment
to achieve an age, race, and sex ratio optimized for statistical
efficiency. African American cases were oversampled to yield a 1:1
Caucasian:African American ratio, and controls were sampled to
match the distribution by race, age, and gender of the cases.
Tissue samples were collected at the time of surgery and fixed in
formalin. Archived formalin-fixed, paraffin-embedded (FFPE)
tissue was provided for DNA isolation and immunohistochemistry
(IHC) in the studies described here. There were 503 total cases
with available tissue for analysis for this study. The University of
California San Diego, San Diego State University, and the
University of Michigan Human Subjects Committees approved
the research utilizing these existing pathological specimens.
DNA Extraction and Microsatellite Analysis
DNA was extracted from formalin-fixed, paraffin-embedded
tissues of each patient’s colorectal tumor and surrounding normal
tissue [14]. Each area microdissected was identified by the
pathologist on a reference hematoxylin and eosin stained slide.
Unstained tissue slices adjacent to the reference slide were
microdissected according to areas identified on the reference slide
using a surgical scalpel blade. The dissected specimen was
deparaffinized in a microfuge tube with xylene, and the DNA
was purified with ethanol and GeneReleaser (BioVentures,
Murfeesboro, TN) according to the manufacturer’s recommenda-
tions. Subsequently, the samples were treated with 200 mg/ml of
proteinase K (Sigma, St. Louis, MO) and incubated at 55uC for
5 hours. The proteinase K was destroyed by heating the sample to
95uC for 15 minutes, and the samples were immediately iced and
stored for polymerase chain reaction (PCR) analysis.
For determination of MSI, we used the NCI-recommended
panel of 5 microsatellite markers (BAT25, BAT26, D5S346,
D2S123, and D17S250) to classify the tumor as MSI-High
(associated with inactivation of DNA MMR), and MSI-Low or
microsatellite stable (MSS) which are not associated with DNA
MMR inactivation. MSI-High was defined as 2 or more markers
demonstrating novel alleles compared to non-tumor tissue, MSI-L
as 1 marker with a novel allele, and MSS as no marker with novel
alleles. Because of the similar features of MSI-Low and MSS
tumors [7], these two groups were included together in our cohort.
One primer from each microsatellite marker pair was radio-
endlabeled with 32P or fluorescently labeled. PCR was carried out
on the microdissected template DNA in a reaction containing
0.125 pmoles each of the endlabeled and ‘‘cold’’ primers, 0.25 U
of Taq DNA polymerase, 40 mM of dNTP stock solution, and final
concentration of 1.5 to 2.0 mM magnesium. PCR products were
denatured in 95% formamide, and electrophoresed on a 6%
polyacrylamide gel containing 7.5 M urea. The gels were then
dried, and exposed by autoradiography to x-ray film or in a
phosphorimager (Molecular Dynamics, Sunnyvale CA). Alterna-
tively, PCR reactions utilizing fluorescently-labeled primers were
sent directly for DNA sequencing.
Genetic analyses were blinded and carried out separately and
independently from the epidemiological data collected in the
study.
Immunohistochemistry and CD8+ T Cell Counts
To perform immunohistochemistry for CD8+ T cells, formalin-
fixed, paraffin-embedded samples were first deparaffinized in
xylene and rehydrated. Endogenous peroxide activity was blocked
with 3% hydrogen peroxide for 20 min. Antigen retrieval was
performed in the microwave for 10 minutes in 10 mM Citrate
Race, MSI, and Colon Cancer
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(pH = 6.0) and 0.05% Tween 20. After cooling, non-specific
protein binding was blocked with 1% BSA in PBS, and
monoclonal mouse anti-human CD8 antibody (DakoCytomation,
Clone C8/144B, Carpinteria, CA) was added overnight at 4uC.
Cells were visualized using the DakoCytomation LSAB2 System-
HRP kit, following the manufacturer’s directions. The slides were
counterstained with Mayer’s hematoxylin, rinsed with ammonium
hydroxide, dried and coverslipped. The samples were then
analyzed by light microscopy.
For cell counts, each slide was evaluated at low power (50X) for
the areas that had the highest concentration of stained cells. Three
high-powered fields (hpf = 100X) were photographed and intra-
epithelial CD8+ T cells were counted independently in each hpf by
two observers. If counts showed discrepancies .10%, the two
observers evaluated the photograph together and then re-counted
independently. The results from the two observers were averaged.
Statistical Analysis
Analyses were conducted using SAS (version 9.1; SAS Institute,
Inc., Cary, NC) and based on 2-sided P values. Statistical analyses
of descriptive values were as follows: for continuous variables, the
T-test; for categorical and pathological values, Fisher’s Exact Test.
We calculated adjusted odds ratios (OR) and 95% confidence
intervals (95% CI) using unconditional logistic regression models
(using the Proc Logistic module of SAS). The following covariates
were considered for inclusion in the multivariate models for
association with MSI cancers: age (continuous), gender (male,
female), cancer stage (classified at time of surgery), race (African
American, Caucasian), mucinous tumor (yes, no), tumor differen-
tiation, inflammatory infiltrate, and cancer location in the colon
(right-sided defined as proximal to the splenic flexure). Significant
interaction was seen between race and tumor site, and there was
weak association interaction between MSI status and age. Models
constructed show both of those interactions.
Data obtained on CD8+ T cell counts/hpf in the total samples
analyzed did not follow a normal, Gaussian distribution; therefore,
non-parametric statistical tests were required to evaluate the
significance of any difference between two groups in each of the
analyses. The Mann-Whitney U test was performed to determine
whether any two independent sample sets had data distributions
that differed significantly. Statistical analyses for CD8+ T cell
counts were performed using IBM SPSS Statistics, version 21.0.0.0
(IBM Corporation, 2012).
P values,0.05 were considered statistically significant.
Results
We utilized a 503-person, true population-based colon cancer
cohort with prospective collection of data from 33 counties in
North Carolina that was designed to oversample African
Americans in the cohort (the North Carolina Colon Cancer
Study, NCCCS) [17]. It is important to note that the MSI analyses
were blinded and carried out separately and independently from
the epidemiological data collected in the study. Among the 503
colon cancers, 227 (45%) were from African Americans, and 276
(55%) were from Caucasians. Overall, 54 (11%) cancers demon-
strated MSI. However, the prevalence of MSI in the cancers
differed between African Americans and Caucasians. There were
39/276 (14%) Caucasians with MSI cancers, compared to 15/227
(7%) African Americans with MSI cancers (Table 1 and Figure
S1). Compared to MSS cancers, MSI cancers were associated with
Caucasian patients (P = 0.009), a mucinous histology (P = 0.0004),
poor differentiation (P = 0.03), a ‘‘Crohn’s-like’’ lymphoid and
intraepitheilial lymphocytic reaction (P = 0.0001), and location in
the proximal colon (P,0.0001) (Table 1). There was no
difference in age, gender, or cancer stage between patients in
the MSI and MSS groups. Except for the racial difference, the
findings associated with MSI tumors were previously known and
serve to validate our data. We performed stepwise regression
assessing all clinicopathological associations, and race, inflamma-
tory infiltrate, and tumor site remained in the final model. There
was significant interaction between race and tumor site. Patients
with MSI cancers have an odds ratio (OR) of 3.21 for the presence
of Crohn’s like histology, and are less likely to be African
Americans (with either proximal cancers, OR = 0.26, or distal
cancers, OR = 0.16) or Caucasians with distal cancers (OR = 0.12)
(Table 2). Adding age, which was weakly related to MSI but not
race, did not significantly alter these odds ratios in the stepwise
regression model.
We assessed whether there were any differences between races
within MSI or MSS cancer groups. We found no difference
between African American and Caucasian patients with MSI
cancers, although there was a trend for African American cancers
to be from younger and female patients (Table 1). Among MSS
cancers, African American patients were significantly younger
(62.6 vs 64.8 years, P = 0.02), more likely female (56% vs. 43%,
P = 0.008), and more likely to have a proximal colon tumor (54%
vs. 44%, P = 0.04) (Table 1). Our data regarding African
American MSS cancers is consistent with African American
females possessing more advanced adenomatous polyps [18], and
SEER and American Cancer Society data consistently showing
earlier age and higher prevalence of proximal colon cancers
among African American patients compared to Caucasian patients
[1,2].
We were able to determine the number of intraepithelial CD8+
T cells within 475 cancers to discern any difference between races,
as higher numbers have been associated with MSI cancers [9] and
improved survival [3,19]. MSI cancers had higher mean CD8+ T
cell counts when compared to MSS cancers (88.0 vs. 30.4/hpf, P,
0.0001) (Figure 1), and this difference was present between MSI
and MSS cancers from African American patients (76.8 vs 32.2/
hpf, P = 0.0057) and from Caucasian patients (95.5 vs. 29.5/hpf,
P,0.0001) (Figure 2). Among MSI cancers, there was no
difference in mean CD8+ T intraepithelial cell infiltration between
African Americans and Caucasians; likewise, there was no
difference between races among MSS cancers (Figure 1). Our
data is consistent with an association between CD8+ T cell
intraepithelial infiltration and MSI cancers. While we observed no
difference for overall mean CD8+ T cell counts between races
(Figure 2), the mean CD8+ T cell count was consistently lower in
African Americans compared to Caucasians (except for MSS
cancers), with little or no representation in the upper quartile of
CD8+ T cell counts (Figure 2A and Figure 1BC). Thus, cancers
with very high infiltration of CD8+ T cells were more often and in
some comparisons almost exclusively from Caucasian patients.
Discussion
This population-based study demonstrates the novel finding that
colon cancers from African American patients have half the
frequency of MSI compared to Caucasians, without apparent
change in the extent of intraepithelial CD8+ T cell infiltration.
This finding is in contrast with two other studies [4,5] that were
not population-based and which utilized stored samples with
linked racial data, and we believe that this study design difference
is the reason for the contrasting results between studies. As MSI is
a good prognostic marker when compared to same-staged patients
with MSS tumors [3], the lesser frequency of MSI among African
Race, MSI, and Colon Cancer
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American colon cancers suggests that this may in part contribute
towards the higher mortlity from colon cancer observed in this
racial group [1,2,20].
The near absence of very high CD8+ T cell counts among
African American cancers might suggest an alteration in immune
function, and this will need to be explored further. However, we
identified no differences when comparing the mean CD8+ T cell
infiltration counts between races for MSI cancers or MSS cancers,
suggesting that race per se is not a determinant of CD8+ T cell
infiltration. Our data confirms the strong association between
CD8+ T cell infiltration and the MSI status of a colon cancer,
consistent with the notion that neoantigens driven by DNA MMR
deficiency and subsequent frameshift mutation of target genes is
operative [8], as well as CD8+ T cells are associated with improved
survival from colon cancer [19]. The strong link between MSI
status and CD8+ T cell infiltration might suggest that CD8+ T
cells are the reason for the observed improved outcome for MSI
tumors. For instance, patients with MSI colon cancers do not
benefit from 5-FU chemotherapy in several studies, and 5-FU
treatment might even decrease survival in these patients [14,15]. It
may be that adenocarcinoma cells with defective DNA MMR
function are resistant to 5-FU, but that the CD8+ T cells are
sensitive to 5-FU, with 5-FU treatment killing the beneficial effect
of the CD8+ T cell infiltration [13]. The absence of very high
CD8+ T cells among African American cancers might simulate a
similar effect as theorized for 5-FU treatment of patients with MSI
cancers.
Table 2. Results of stepwise regression model for co-variables for MSI versus MSS cancers.
Infiltrate
Odds Ratio for MSI Cancer
(without age in model) Confidence Intervals
Odds Ratio for MSI Cancer
(with age in model) Confidence Intervals
Lymphocytic 1.0 referent 1.0 referent
Crohn’s-like 3.21 1.68, 6.13 3.19 1.67, 6.09
Race-Site
CA-Right 1.0 referent 1.0 referent
CA -Left 0.12 0.04, 0.33 0.12 0.05, 0.33
AA-Right 0.26 0.11, 0.60 0.26 0.11, 0.61
AA-Left 0.16 0.05, 0.48 0.17 0.06, 0.51
CA = Caucasian American; AA = African American; Right = colon proximal to and including the splenic flexure; Left = colon distal to the splenic flexure.
doi:10.1371/journal.pone.0100461.t002
Figure 1. CD8+ T cell infiltration in colon cancers. (A) Immunohistochemistry of CD8+ T cells within malignant epitheilial glands of a colon
cancer. Note the presence of intraepithelial CD8+ T cells (inset). (B) CD8+ T cell counts between MSI and MSS cancers. (C) CD8+ T cell counts of MSI
cancers between races. (D) CD8+ T cell counts of MSS cancers between races. Note there is no difference between African Americans and Caucasians
comparing MSI or MSS cancers. The number above each dot blot are means; the horizontal bar represents the mean number among the cancers.
doi:10.1371/journal.pone.0100461.g001
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Another biomarker of defective DNA MMR in sporadic
colorectal cancers is elevated microsatellite alterations at selected
tetranucelotide repeats, or EMAST, found in up to 60% of
colorectal cancers and caused by somatic inactivation of hMSH3
[21,22]. EMAST is associated with metastasis and poor prognosis
[23,24] and appears to be twice as common among rectal cancers
from African Americans compared with Caucasians [24]. Thus,
the contribution of EMAST, a poor prognosticator for patients
with colon cancer, coupled with reduced prevalence of MSI, a
good prognosticator, together make up two biological processes
involved with inflammation and defects of DNA MMR that may
worsen the outcome of African American patients with colon
cancer.
Our data also demonstrate the predominant proximal nature of
colon cancer in African Americans that is not due to MSI. Or data
is consistent with prior SEER and American Cancer Society data
[1], but highlight the right-sided nature of cancers in the absence
of MSI tumors. Why there are more proximal colon cancers in
African American patients is not known. However, this has
implications for the approach to colon cancer screening in this
population.
In conclusion, we find half the prevalence of MSI among
African American patients with colon cancer as compared to
Causcasian patients without change in CD8+ T cell infiltration.
This finding may contribute towards African Americans’ higher
mortality from colon cancer.
Supporting Information
Figure S1 Distribution of MSI and MSS tumors among African
American and Caucasian patients in the NCCCS.
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